Frequency Therapeutics terminates ATM equity agreement, transfers Nasdaq listing to Capital Market

Korro Bio, Inc.

Terminated Equity Distribution Agreement with Oppenheimer; only $50,000 in net proceeds raised from 12,767 shares sold.
Nasdaq approved transfer from Global Select Market to Capital Market effective Sept 28, 2023.
Extended bid price compliance period to March 25, 2024; company plans reverse stock split if needed.
Merger with Korro Bio remains pending; S-4 registration statement already filed.

item 1.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Korro Bio, Inc. terminated Sales Agreement with Oppenheimer & Co. Inc. (effective 2023-09-26).

Action: termination
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc.
Effective: 2023-09-26

Exact text from the filing

On September 26, 2023, the Company delivered written notice to Oppenheimer of termination of the Sales Agreement pursuant to Section 11(b) thereof, effective immediately.

View on SEC.gov

15 material agreements filed in the last 30 days. Browse all material agreements →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-243671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.